Macquarie Group Ltd. boosted its position in shares of CryoLife, Inc. (NYSE:CRY) by 18.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,387,710 shares of the medical equipment provider’s stock after purchasing an additional 217,283 shares during the period. Macquarie Group Ltd. owned about 4.15% of CryoLife worth $27,685,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Wells Fargo & Company MN lifted its holdings in CryoLife by 16.5% during the 1st quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock valued at $517,000 after purchasing an additional 4,399 shares during the last quarter. Royce & Associates LP lifted its holdings in CryoLife by 10.0% during the 2nd quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock valued at $8,682,000 after purchasing an additional 39,500 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in CryoLife by 4.6% during the 1st quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock valued at $2,714,000 after purchasing an additional 7,228 shares during the last quarter. William Blair Investment Management LLC bought a new position in CryoLife during the 2nd quarter valued at about $4,517,000. Finally, Vanguard Group Inc. lifted its holdings in CryoLife by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after purchasing an additional 43,212 shares during the last quarter. 68.44% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Macquarie Group Ltd. Has $27.69 Million Position in CryoLife, Inc. (CRY)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/11/macquarie-group-ltd-has-27-69-million-position-in-cryolife-inc-cry.html.

In other news, Director James Benson sold 2,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $22.80, for a total value of $45,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 43,050 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. Insiders sold 171,050 shares of company stock valued at $3,769,825 in the last three months. Company insiders own 6.00% of the company’s stock.

Several equities analysts recently issued reports on the stock. Canaccord Genuity reissued a “buy” rating and set a $25.00 price target on shares of CryoLife in a report on Monday. Lake Street Capital lifted their price target on shares of CryoLife to $26.00 and gave the company a “buy” rating in a report on Wednesday. BidaskClub downgraded shares of CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Finally, Zacks Investment Research raised shares of CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.63.

CryoLife, Inc. (CRY) opened at 23.30 on Wednesday. The company has a market capitalization of $779.29 million, a P/E ratio of 70.61 and a beta of 0.92. The company’s 50-day moving average is $21.82 and its 200 day moving average is $19.17. CryoLife, Inc. has a one year low of $14.03 and a one year high of $24.00.

CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. The firm had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share. Analysts predict that CryoLife, Inc. will post $0.43 EPS for the current year.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.